Veeva Systems (NYSE: VEEV) today announced Boehringer Ingelheim is the latest top 20 biopharma to standardize customer data ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...

LEO Pharma and Boehringer Ingelheim have entered into a partnership to commercialise and advance the development of ...

"Longer follow-ups after the pandemic are needed to investigate persistent brain aging effects and their long-term ...

The FDA approved Anzupgo for the treatment of moderate to severe chronic hand eczema in adults who do not adequately respond ...

The data from 2019 to 2023 show rapid uptake of the drugs alongside wide patient- and practice-level variations.

Lupin is releasing Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%, which are the generic of Boehringer ...

New research from investigators at Mass General Brigham suggests that a commonly used type 2 diabetes medication is linked to a higher rate of heart-related conditions compared to medications that hit ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...